Novel Cell‐Free DNA Screening Assay Validated for Trisomies
By LabMedica International staff writers Posted on 10 Sep 2019 |
Image: The Vanadis Core Cell-Free DNA analysis unit (Photo courtesy of PerkinElmer).
Prenatal screening for trisomies 21, 18, and 13 is currently performed using multiple maternal serum and ultrasound markers. Clinical implementation studies of maternal plasma cell‐free (cf)-DNA testing have demonstrated a much higher sensitivity and specificity for these trisomies.
However, where cfDNA screening has been adopted in public health programs, it is mostly as a second‐tier test. Health economic analyses have identified the necessity of more cost‐effective cfDNA tests to enable a wide adoption of first‐line screening. Targeted tests are based on high complexity genetic analysis platforms that require a relatively advanced laboratory setup.
An international collaboration of scientists led by those at Vanadis Diagnostics (PerkinElmer, Sollentuna, Sweden) analyzed maternal plasma samples from 1,200 singleton pregnancies, which included 158 fetal aneuploidies. Reference outcomes were determined by amniocentesis or chorionic villi sampling (CVS), followed by cytogenetic testing, such as karyotyping, fluorescence in situ hybridization (FISH) or quantitative fluorescence-polymerase chain reaction (QF‐PCR) or clinical examination of neonates.
Processing and analysis of plasma samples was performed using the Vanadis noninvasive prenatal testing (NIPT) was performed blinded to the reference outcomes. The automated Vanadis NIPT assay targets specific chromosomes based on digital molecular quantification in a 96‐well microplate format. The assay enables automated high precision cfDNA analysis from primary blood tubes. The Vanadis NIPT assay relies on a series of enzymatic steps that specifically generate labeled rolling circle replication products (RCPs) from chromosomal cfDNA targets.
The scientists reported that the assay sensitivity was 100% (112/112) for trisomy 21 (Down syndrome), 89% (32/36) for trisomy 18 (Edwards syndrome), and 100% (10/10) for trisomy 13 (Patau syndrome). The respective specificities were 100%, 99.5%, and 99.9%. There were five first pass failures (0.4%), all in unaffected pregnancies. Sex classification was performed on 979 of the samples and 99.6% (975/979) provided a concordant result.
Masoud Toloue, PhD, vice president and general manager of Diagnostics at PerkinElmer, the parent company of Vanadis, said, “We continue to be encouraged by clinical studies that further validate our Vanadis platform as a reliable, cost-effective solution for laboratories and obstetricians to offer aneuploidy screening. Our Vanadis platform eliminates the technical complexity of NIPT, giving more women access to cfDNA screening for common trisomies and further improving prenatal care on a global scale.”
The authors concluded that the study demonstrated that cfDNA testing with the highly automated Vanadis NIPT system does not require specialized personnel for screening. The Vanadis system is also designed to help reduce cost and allow wider population-based screening. The study was published on August 19, 2019, in the journal Prenatal Diagnosis.
Related Links:
Vanadis Diagnostics
However, where cfDNA screening has been adopted in public health programs, it is mostly as a second‐tier test. Health economic analyses have identified the necessity of more cost‐effective cfDNA tests to enable a wide adoption of first‐line screening. Targeted tests are based on high complexity genetic analysis platforms that require a relatively advanced laboratory setup.
An international collaboration of scientists led by those at Vanadis Diagnostics (PerkinElmer, Sollentuna, Sweden) analyzed maternal plasma samples from 1,200 singleton pregnancies, which included 158 fetal aneuploidies. Reference outcomes were determined by amniocentesis or chorionic villi sampling (CVS), followed by cytogenetic testing, such as karyotyping, fluorescence in situ hybridization (FISH) or quantitative fluorescence-polymerase chain reaction (QF‐PCR) or clinical examination of neonates.
Processing and analysis of plasma samples was performed using the Vanadis noninvasive prenatal testing (NIPT) was performed blinded to the reference outcomes. The automated Vanadis NIPT assay targets specific chromosomes based on digital molecular quantification in a 96‐well microplate format. The assay enables automated high precision cfDNA analysis from primary blood tubes. The Vanadis NIPT assay relies on a series of enzymatic steps that specifically generate labeled rolling circle replication products (RCPs) from chromosomal cfDNA targets.
The scientists reported that the assay sensitivity was 100% (112/112) for trisomy 21 (Down syndrome), 89% (32/36) for trisomy 18 (Edwards syndrome), and 100% (10/10) for trisomy 13 (Patau syndrome). The respective specificities were 100%, 99.5%, and 99.9%. There were five first pass failures (0.4%), all in unaffected pregnancies. Sex classification was performed on 979 of the samples and 99.6% (975/979) provided a concordant result.
Masoud Toloue, PhD, vice president and general manager of Diagnostics at PerkinElmer, the parent company of Vanadis, said, “We continue to be encouraged by clinical studies that further validate our Vanadis platform as a reliable, cost-effective solution for laboratories and obstetricians to offer aneuploidy screening. Our Vanadis platform eliminates the technical complexity of NIPT, giving more women access to cfDNA screening for common trisomies and further improving prenatal care on a global scale.”
The authors concluded that the study demonstrated that cfDNA testing with the highly automated Vanadis NIPT system does not require specialized personnel for screening. The Vanadis system is also designed to help reduce cost and allow wider population-based screening. The study was published on August 19, 2019, in the journal Prenatal Diagnosis.
Related Links:
Vanadis Diagnostics
Latest Molecular Diagnostics News
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access